CVS Health Corporation Stock Price and Value Analysis

CVS Health Corporation (NYSE:CVS) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

  • Ticker: CVS (NYSE)
  • Current price: $80.84
  • Sector: Unknown
  • Industry: Unknown
  • Dividend yield: 3.32%

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold CVS Health Corporation to reach your target.

Target type

CVS Free Cash Flow Trend

Free Cash Flow trendline for CVS
Free Cash Flow trendline for CVS Health Corporation
CSV

Based on historical returns, we believe that CVS Health Corporation can grow its free cash at a rate of about 5%. That's positive!

AdvantagesDisadvantages
  • This company is very stable.
  • This stock is available at a great discount!
  • This company has a large dividend yield!
  • This company has wild ups and downs.
  • This company is making money at a modest rate.

Inside the CVS Numbers

CVS Price
(CVS Health Corporation stock price per share)
$80.84
[?] CVS Fair Price
(based on intrinsic value)
$160.24
[?] CVS Safety Price (based on a variable margin of safety) $128.19
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 131% higher than other Unknown stocks
[?] PE Ratio versus Industry 4% higher than other Unknown stocks
[?] Cash Yield 7.86%
[?] Free Cash Flow Jitter 37%
[?] Dividend Yield 3.32% (tax impact)
Shares Shorted 17,875,527

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by CVS Health Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2021-09-02 Brennan Troyen A (EVP and Chief Medical Officer) Sell 2,625 $87.00

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 17,875,527 shares shorted. With 1,276,966,419 shares available for purchase and an average trading volume over the past 10 trading days of 13,228,320, it would take at least 1.4 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 64803 1,425
2008 64803 1,955
2009 64803 1,857
2010 64803 2,645
2011 64803 3,774
2012 64803 4,544
2013 64803 3,695
2014 64803 6,132
2015 64803 6,461
2016 64803 7,993
2017 64803 5,881
2018 64803 6,729
2019 64803 10,647
2020 64803 13,650
2021 64803 15,991
2022 64803 13,741
2023 64803 10,792
2024 64803 6,408
2025 64803 7,861

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 15 fiscal years from 2007 to 2025 with positive net income, operating cash flow totaled $147,142 million against net income of $75,629 million, or 1.95 times. Net income was negative in 1 of the 16 years, and those years are left out of the ratio.

In 2025, operating cash flow was 6.02 times net income, compared with 1.18 times for the earliest three years (2007 to 2009).

In 2025, capital expenditures were $2,832 million, 26.6% of operating cash flow of $10,639 million, which leaves an estimated $7,807 million after capex. Across the 16 years with reported capex, it averaged 24.4% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2007 2,637 3,230 1,805 1.22
2008 3,198 3,947 2,180 1.23
2009 3,696 4,035 2,548 1.09
2010 3,427 4,779 2,005 1.39
2014 4,644 8,137 2,136 1.75
2015 5,237 8,539 2,367 1.63
2016 5,317 10,141 2,224 1.91
2017 6,622 8,007 1,918 1.21
2018 -594 8,865 2,037 n/a
2019 6,634 12,848 2,457 1.94
2020 7,179 15,865 2,437 2.21
2021 8,001 18,265 2,520 2.28
2022 4,311 16,177 2,727 3.75
2023 8,344 13,426 3,031 1.61
2024 4,614 9,107 2,781 1.97
2025 1,768 10,639 2,832 6.02

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $99,693 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $26,588 million, 26.7% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 5 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $17,357 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends paid were $3,397 million, 43.2% of estimated free cash flow of $7,861 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 7,993 1,840 4,461 6,301 78.8%
2017 5,881 2,049 4,361 6,410 109.0%
2018 6,729 2,038 n/a 2,038 30.3%
2019 10,647 2,603 n/a 2,603 24.4%
2020 13,650 2,624 n/a 2,624 19.2%
2021 15,991 2,625 n/a 2,625 16.4%
2022 13,741 2,907 3,500 6,407 46.6%
2023 10,792 3,132 2,012 5,144 47.7%
2024 6,408 3,373 3,023 6,396 99.8%
2025 7,861 3,397 n/a 3,397 43.2%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $76,330 million in 2007 and $402,067 million in 2025, a compound annual growth rate of 9.7% over 18 years.

Revenue rose 7.8% from 2024 to 2025.

Our estimated free cash flow was $7,861 million in 2025, 2.0% of revenue. In 2007 the estimated margin was 1.9%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 76,330 1,425 1.9%
2008 87,472 1,955 2.2%
2009 98,215 1,857 1.9%
2010 95,778 2,645 2.8%
2011 107,080 3,774 3.5%
2012 123,120 4,544 3.7%
2013 126,761 3,695 2.9%
2014 139,367 6,132 4.4%
2015 153,290 6,461 4.2%
2016 177,546 7,993 4.5%
2017 184,786 5,881 3.2%
2018 194,579 6,729 3.5%
2019 256,776 10,647 4.1%
2020 268,706 13,650 5.1%
2021 292,111 15,991 5.5%
2022 322,467 13,741 4.3%
2023 357,776 10,792 3.0%
2024 372,809 6,408 1.7%
2025 402,067 7,861 2.0%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $8,453 million against total liabilities of $178,156 million, or 4.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 70.3% of total assets in 2025, compared with 43.3% in 2008, an increase of 27.0 percentage points.

Stockholders equity was $75,382 million in 2025, compared with $34,574 million in 2008, a rise of 118.0%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 5.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 60,960 1,352 26,386 34,574
2009 61,641 1,086 25,873 35,768
2010 62,169 1,427 24,469 37,700
2011 64,852 1,413 26,530 38,013
2012 66,221 1,375 28,568 37,653
2013 71,526 4,089 33,588 37,938
2014 74,187 2,481 36,224 37,963
2015 92,437 2,459 55,195 37,203
2016 94,462 3,371 57,628 36,834
2017 95,131 1,696 57,436 37,695
2018 196,456 4,059 137,913 58,543
2019 222,449 5,683 158,279 64,170
2020 230,715 7,854 161,014 69,701
2021 232,999 9,408 158,158 75,381
2022 228,275 12,945 156,506 71,769
2023 249,728 8,196 173,092 76,636
2024 253,215 8,586 177,485 75,730
2025 253,538 8,453 178,156 75,382

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $80.84, our model's value equals that price if free cash flow grows an average of -17.3 percent a year over the 10 projection years. Our model assumes 4.8 percent a year for this stock, so the price implies growth of -17.3 percent, which is below the 4.8 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $8,130 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $64.67 below range
Current price $80.84 -17.3%
20 percent above the current price $97.01 -8.9%
Our model (stored fair price) $160.24 4.8%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

Free cash flow was positive in all 19 fiscal years we have for CVS Health Corporation under its current SEC filer.

The latest three years average $8,353 million in free cash flow against $1,746 million for the earliest three, which is a sharp rise.

Free cash flow is volatile from year to year, with a variability measure of 37%.

At $80.84, the stock is under our safe value of $128.19, against a fair value estimate of $160.24.

The dividend yield for CVS Health Corporation is 3.32%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 64803.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: CVS annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in CVS

Does CVS Health Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: CVS

This example shows how we apply the Trendshare checklist to CVS: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 80.84
    • Market cap: $103B
    • EPS: 8.61
  2. Step 2 — Valuation checks

    • P/E: 9.389
    • FCF yield: 7.9%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.